Ameriprise
ASND icon

Ameriprise’s Ascendis Pharma A/S ASND Stock Holding History

Ameriprise’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-411,500
Closed -$94.1M – 4110
2026
Q1 		$94.1M Buy
+411,500
New +$92.2M 0.02% 576

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ameriprise's ASND Position: Q2 2026 in Review

Ameriprise reduced its Ascendis Pharma A/S (ASND) stake by 33% in Q2 2026, selling an estimated $36.4M and leaving 320,514 shares worth $85.5M. The position accounts for 0.02% of the portfolio, ranked #671.

Ameriprise first reported a position in ASND in Q1 2019 and has held it in 30 quarters since. The position peaked at $117M in Q4 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Ameriprise held 320,514 shares of Ascendis Pharma A/S worth $85.5M as of Q2 2026.
  • Ameriprise sold 155,952 Ascendis Pharma A/S shares in Q2 2026, an estimated $36.4M.
  • Ascendis Pharma A/S made up 0.02% of Ameriprise's portfolio in Q2 2026, its #671 holding.
  • Ameriprise first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 30 quarters since.
  • Ameriprise's Ascendis Pharma A/S position peaked at $117M in Q4 2025.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.